权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting metabolic stress to induce pancreatic tumor cell death

针对代谢应激诱导胰腺肿瘤细胞死亡

基本信息

批准号：
10656461
负责人：
Costas Andreas Lyssiotis
金额：
$ 38.31万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-01 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10656461
关键词：
3-Dimensional Anabolism Apoptosis Biological Assay Cancer Etiology Carbon Cause of Death Cell Death Cells Cessation of life Chemicals Clinical Treatment Cysteine Cysteine Metabolism Pathway Data Dependence Diet Disease Drug Targeting Environment Enzymes Equilibrium Exhibits Fibroblasts Foundations Genetic Genetic Models Genetic Techniques Glutamates Glutathione Growth Human Immunotherapy Impairment In Vitro Incidence Iron Knock-out Lipid Peroxidation Malignant Neoplasms Malignant neoplasm of pancreas Measures Mediating Metabolic Metabolic Pathway Metabolic stress Metabolism Methods Modeling Mutation NADP Nutrient Oxaloacetates Oxidation-Reduction Pancreas Pancreatic Ductal Adenocarcinoma Pathway interactions Patients Pharmaceutical Preparations Pharmacotherapy Pre-Clinical Model Process Property Reactive Oxygen Species Regulation Research Proposals Resistance Role Safety Stress Sulfur Survival Rate Techniques Testing Therapeutic Transaminases Translations Treatment Efficacy United States cancer cell effective therapy experimental study extracellular in vivo inhibitor insight interest knock-down metabolomics mitochondrial metabolism mouse model new therapeutic target novel therapeutic intervention pancreatic cancer cells pancreatic ductal adenocarcinoma cell pancreatic ductal adenocarcinoma model pancreatic neoplasm pharmacologic programs protective pathway stable isotope stressor three dimensional cell culture translational potential tumor tumor growth uptake

项目摘要

ABSTRACT Pancreatic cancer is a devastating disease with a five-year survival rate below 10%. One of the main factors underscoring this low survival rate is the lack of effective clinical treatments. Like most cancers, metabolic processes in pancreatic cancer cells are altered to facilitate macromolecular biosynthesis and protect against intra and extracellular stressors. Reactive oxygen species (ROS) are a byproduct of metabolism and represent a notable metabolic stress to pancreatic cancer cells. Previously, we described a new metabolic pathway in pancreatic cancer, mediated by cytosolic glutamate oxaloacetate transaminase 1 (GOT1), that is used to manage ROS by facilitating the coordination of cytosolic and mitochondrial metabolism and maintaining glutathione (GSH) pools. Ferroptosis is a recently described form of iron-dependent, non-apoptotic cell death caused by lipid peroxidation and mediated by loss of GSH pools. We found that GOT1 inhibition potentiated the activity of known ferroptotic agents. Further, we also discovered that GOT1 inhibition can engage ferroptosis when nodes in cysteine metabolism are inhibited. In this research proposal, we will determine how GOT1 inhibition promotes ferroptosis. Mechanistic insight from these studies will then be used to selectively target pancreatic cancers for ferroptotic cell death. This will be accomplished using metabolomics techniques in combination with genetic and pharmacological inhibitors of metabolism. In parallel, we will test combinations of ferroptotic agents with GOT1 inhibition in human patient-derived 3D culture models and in orthotopic mouse models to determine the translation value. Given the safety profile of GOT1 and some ferroptosis-inducers, the profound sensitivity of this combination in pancreatic cancer cells, and the desperate need for new strategies to treat pancreatic cancer, there is now a critical need to understand mechanistically what confers sensitivity to these combinations. Such insights may provide strategies to promote redox imbalance in pancreatic cancer, paving the way for tumor-selective, ferroptosis-based therapies.

摘要

项目成果

期刊论文数量（6）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer.

DOI：
10.1101/gad.344184.120
发表时间：
2021-02-01
期刊：
Genes & development
影响因子：
10.5
作者：
Purohit V;Wang L;Yang H;Li J;Ney GM;Gumkowski ER;Vaidya AJ;Wang A;Bhardwaj A;Zhao E;Dolgalev I;Zamperone A;Abel EV;Magliano MPD;Crawford HC;Diolaiti D;Papagiannakopoulos TY;Lyssiotis CA;Simeone DM
通讯作者：
Simeone DM

Clinical Targeting of Altered Metabolism in High-Grade Glioma.